{"doi":"10.2217/fon.14.313","title":"Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer","abstract":null,"journal":"Future Oncology","year":2015,"id":631588,"datarank":3.834668151433798,"base_score":4.543294782270004,"endowment":4.543294782270004,"self_citation_contribution":0.6814942173405006,"citation_network_contribution":3.1531739340932976,"self_endowment_contribution":0.6814942173405006,"citer_contribution":3.1531739340932976,"corpus_percentile":null,"corpus_rank":null,"citation_count":93,"citer_count":89,"citers_with_citation_signal":74,"citers_with_endowment":74,"datacite_reuse_total":4,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1636852,"name":"Kathleen N Moore","orcid":null,"position":1,"is_corresponding":false},{"id":1636850,"name":"Camille C Gunderson","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer","abstract":"Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular compatibility with the drug's mechanism of action.","is_dataset_classified":null,"base_score":4.543294782270004,"endowment":4.543294782270004,"datacite_reuse_total":4,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25757679","pmcid":null,"openalex_id":"https://openalex.org/W2164296043","authors":[],"funders":[],"total_grants":0,"fwci":2.8853,"citation_percentile":0.93001281,"influential_citations":0,"citation_trend":[{"year":2015,"count":2},{"year":2016,"count":12},{"year":2017,"count":5},{"year":2018,"count":3},{"year":2019,"count":7},{"year":2020,"count":12},{"year":2021,"count":9},{"year":2022,"count":17},{"year":2023,"count":7},{"year":2024,"count":5},{"year":2025,"count":9},{"year":2026,"count":5}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon.14.313","host_type":"publisher"},{"url":"https://doi.org/10.2217/fon.14.313","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25757679","host_type":"repository"}],"fields_of_study":["PARP inhibition in cancer therapy","Toxin Mechanisms and Immunotoxins","Administration, Oral","Animals","Antineoplastic Agents","Clinical Trials as Topic","Drug Evaluation, Preclinical","Female","Humans","Ovarian Neoplasms","Phthalazines","Piperazines","Poly (ADP-Ribose) Polymerase-1","Poly(ADP-ribose) Polymerase Inhibitors","Poly(ADP-ribose) Polymerases","Treatment Outcome"],"mesh_terms":["Poly(ADP-ribose) Polymerase Inhibitors","Poly (ADP-Ribose) Polymerase-1","Administration, Oral","Animals","Antineoplastic Agents","Clinical Trials as Topic","Drug Evaluation, Preclinical","Female","Humans","Ovarian Neoplasms","Phthalazines","Piperazines","Poly(ADP-ribose) Polymerases","Treatment Outcome"],"keywords":["Olaparib","PARP inhibitor","Medicine","Ovarian cancer","Poly ADP ribose polymerase","Oncology","Cancer research","Cancer","Internal medicine","Gynecology","Polymerase","Genetics","Biology","DNA","Brca Mutation","Homologous Recombination Pathway"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.20423710.v1","title":"Additional file 1 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20423710","title":"Additional file 1 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20423713","title":"Additional file 2 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.20423713.v1","title":"Additional file 2 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer","publisher":"figshare","resource_type":"Dataset"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T00:06:55.291573Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}